BDTX - Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor.

As of Jun 30, 2026: spot at $1.85, ATM IV 180.2%, max pain $2.00, net GEX $2.9K.

Sector
Healthcare
Industry
Biotechnology
Market Cap
$98.0M
Beta
3.23
52-Week Range
1.6-4.94
CEO
Mark A. Velleca
Employees
24
IPO Date
Jan 31, 2020
Exchange
NASDAQ

What BDTX Looks Like to Options Traders Today

IV rank of 34.5% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($2.9K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.362) prices calls richer than puts, often reflecting upside speculation or squeeze risk.

What This Page Covers

The BDTX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.

Frequently asked BDTX overview questions

What is BDTX?
BDTX is the ticker symbol for Black Diamond Therapeutics, Inc., a listed security. Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. Listed on NASDAQ. BDTX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
What does the BDTX options snapshot look like today?
As of Jun 30, 2026, the BDTX options snapshot shows spot at $1.85, ATM IV 180.2%, IV rank 34.5%, max pain $2.00, net GEX $2.9K, expected move 51.66%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
What are BDTX's key statistics?
Black Diamond Therapeutics, Inc. (BDTX) carries a market capitalization of $98.0M, beta of 3.23 relative to the broader market, 52-week range of 1.6-4.94. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
What sector or industry does BDTX belong to?
Black Diamond Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare BDTX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
How current is the BDTX data on this page?
The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).